Aurobindo Pharma Limited, a key player in the global pharmaceuticals market, has once again demonstrated remarkable financial health in the first quarter of fiscal year 2025. The company announced a 10.5% increase in revenue from operations, totaling INR 7,567 crore. This surge is attributed to consistent growth across all business sectors, particularly in the United […]
Aurobindo Pharma Limited, a leading player in the pharmaceutical sector, has announced its consolidated financial results for the quarter ended December 31, 2023. The company reported a robust 14.7% year-on-year increase in revenue from operations, amounting to INR 7,352 Cr, showcasing growth across multiple business segments. The US formulations segment, excluding Puerto Rico, witnessed a […]
Aurobindo Pharma Limited has achieved a significant milestone by securing the US Food and Drug Administration (FDA)’s tentative nod under the PEPFAR program for its generic dispersible tablet, a fixed-dose combination of Abacavir 60mg, Lamivudine 30 mg, and Dolutegravir 5 mg (pALD). This formulation is pivotal for treating children afflicted with HIV, particularly those weighing […]
Aurobindo Pharma, along with its subsidiary Eugia Pharma Specialities has announced a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market Nilotinib Capsules. Originally developed by Novartis, Nilotinib Capsules are used for the treatment of chronic myeloid leukemia (CML) in 44 low and middle-income countries (LMIC). This agreement covers seven countries where […]
Aurobindo Pharma has secured consent from the Drugs Controller General of India (DCGI) for manufacturing and distributing its generic version of Covid drug Molnupiravir under the brand name — Molnaflu. The Indian pharma company had previously acquired the licensing rights for the generic version of MSD and Ridgeback Biotherapeutics’ Molnupiravir. A non-exclusive voluntary licensing agreement […]